Belite Bio to Seek FDA Approval for its Stargardt Disease Drug from Foundation Fighting Blindness

Belite Bio to Seek FDA Approval for its Stargardt Disease Drug

3 minutes Posted Dec 2, 2025 at 7:28 pm.

0:00

3:06

Share at current time

Show notes

Tinlarebant slowed disease progression by 36 percent in the Dragon Phase 3 clinical trial.